NCT05292352

Brief Summary

This is a 2 year clinical trial testing an intensive intervention to reduce dietary sugars as a means to prevent non-alcoholic fatty liver disease (NAFLD) in pre-pubertal Hispanic children.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
103

participants targeted

Target at P50-P75 for not_applicable

Timeline
11mo left

Started Apr 2022

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress83%
Apr 2022Mar 2027

First Submitted

Initial submission to the registry

March 15, 2022

Completed
8 days until next milestone

First Posted

Study publicly available on registry

March 23, 2022

Completed
14 days until next milestone

Study Start

First participant enrolled

April 6, 2022

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2026

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2027

Expected
Last Updated

March 13, 2026

Status Verified

February 1, 2026

Enrollment Period

4 years

First QC Date

March 15, 2022

Last Update Submit

March 11, 2026

Conditions

Keywords

Latino ChildrenPre-puberalLow Free sugar diet (LFSD)

Outcome Measures

Primary Outcomes (2)

  • Change in Percent Hepatic Steatosis by MRI-PDFF

    The primary objective for the 12-month study is to test if an LFSD, compared to usual diet protects against increase in hepatic steatosis

    12 month after start of intervention

  • Onset of NAFLD

    The primary objective for the 24-month is to study to test if an LFSD protects against development of NAFLD (hepatic steatosis ≥ 5% and elevated ALT).

    24 months after start of intervention

Secondary Outcomes (12)

  • Changes in markers of liver inflammation: ALT

    Baseline, month 6, month 12, month 18, and month 24

  • Changes in markers of liver inflammation: AST

    Baseline, month 6, month 12, month 18, and month 24

  • Changes in markers of liver inflammation: GGT

    Baseline, month 12 and month 24

  • Changes in HbA1c

    Baseline, month 12 and month 24

  • Changes in fasting triglycerides

    Baseline, Month 6, Month 12, month 18 and month 24

  • +7 more secondary outcomes

Study Arms (2)

Low Free Sugar Diet (LFSD) Intervention

EXPERIMENTAL

The 1-year dietary intervention will be accomplished by adapting and extending a Social Cognitive Theory (SCT) guided low sugar intervention. SCT is a framework that helps explain how people regulate their behavior through control and reinforcement to achieve goal-directed behavior that can be maintained over time.

Behavioral: LFSD

Usual Care Control

NO INTERVENTION

Usual Care (Control group): Parents of enrolled children in the usual care group will be provided printed material on healthy family lifestyle at the beginning of the study. The control group will complete all of the same research visits and assessments as the intervention group.

Interventions

LFSDBEHAVIORAL

Assessment of child's usual diet to assess sugar intake in relation to the total usual diet. Consultation with a nutritionist to help families identify foods high in sugar. Removal of foods and drinks high in free sugar from the home. Counseling using motivational interviewing, patient-centered goal setting to help parents and participating youth identify barriers to compliance with the intervention. Provision of a study provided LFSD with sufficient quantity to meet the needs and adapted to meet the preferences of the entire household for the first 4 weeks. Facilitated grocery shopping trips every 3 months during year 1.

Low Free Sugar Diet (LFSD) Intervention

Eligibility Criteria

Age6 Years - 9 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • At least one parent or the child self-identifies as Hispanic or Latino.
  • BMI ≥ 50th percentile for age and sex.
  • Age ≥ 6 years and ≤ 9 years
  • Tanner stage 1 by self and/or parental report
  • Normal ALT on screening labs (≤23 IU for girls, ≤26 IU for boys)
  • Written informed consent from parent or legal guardian, assent from child

You may not qualify if:

  • Known diagnosis of chronic liver disease other than NAFLD and "fatty liver"
  • History of significant depression
  • Implanted metal or other implant (braces ok), or claustrophobia or other reason that contraindicates MRI
  • Type 2 diabetes (Hemoglobin A1c \> 6.4% on screening labs or chronic diagnosis)
  • Plans to move within the next 12 months
  • Current or previous participation in a weight loss program or obesity treatment program or clinic
  • Cancer or history of cancer
  • Recipient of a liver transplant
  • Chronic use (in the last year) of medications known to cause NAFLD or fatty liver (TPN, amiodarone, chronic oral steroids, etc.)
  • Intellectual disability or major psychiatric disorder limiting informed assent
  • At risk for eating disorder by screening instrument
  • Participants who are currently enrolled in a clinical trial or have received an investigational product within the last 60 days
  • Participants who are not able or willing to comply with the diet protocol or have any other condition or circumstance that would impede compliance or hinder completion of the study in the opinion of the investigator
  • Children who spend more than 1 night per week consistently in another household

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Emory University

Atlanta, Georgia, 30329, United States

Location

Related Publications (1)

  • Welsh JA, Pyo E, Huneault H, Gonzalez Ramirez L, Alazraki A, Alli R, Dunbar SB, Khanna G, Knight-Scott J, Pimentel A, Reed B, Rodney-Somersall C, Santoro N, Umpierrez G, Vos MB. Study protocol for a randomized, controlled trial using a novel, family-centered diet treatment to prevent nonalcoholic fatty liver disease in Hispanic children. Contemp Clin Trials. 2023 Jun;129:107170. doi: 10.1016/j.cct.2023.107170. Epub 2023 Apr 3.

MeSH Terms

Conditions

Non-alcoholic Fatty Liver Disease

Condition Hierarchy (Ancestors)

Fatty LiverLiver DiseasesDigestive System Diseases

Study Officials

  • Jean Welsh, PhD, MPH, RN

    Emory University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

March 15, 2022

First Posted

March 23, 2022

Study Start

April 6, 2022

Primary Completion

March 31, 2026

Study Completion (Estimated)

March 31, 2027

Last Updated

March 13, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will share

De-identified data underlying published findings

Shared Documents
STUDY PROTOCOL
Time Frame
Data will be made available 6 months after publication. Applications must be submitted within 24 months of publication date.
Access Criteria
Researchers who provide a methodologically sound proposal, to achieve aims in an approved proposal. Access will be granted by submitting written detailed proposal to the corresponding author of the published article.

Locations